Equity Profile

SRRK

Scholar Rock Holding Corporation

Health CareBiotechnology$5.9B

May7Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:00 AM EDT

Scholar Rock Holding Corporation Misses on EPS, Stock Down 1.4%

Metric	Actual	Expected	Surprise
EPS	$-0.83	$-0.78	-1.59%
Revenue	$0M	$0M	—

management commentary, guidance changes, and full analysis available with Pro.

Scholar Rock Holding Corporation Misses on EPS, Stock Down 1.4%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.83	$-0.78	-1.59%
Revenue	$0M	$0M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Scholar Rock's earnings report shows a larger-than-expected loss per share, which likely contributed to the stock's decline of 1.4%. The lack of revenue and guidance may raise concerns among investors about the company's short-term prospects. Overall, the results indicate challenges ahead for Scholar Rock as it navigates its financial landscape.

Company Snapshot

Scholar Rock Holding Corporation operates in the biotechnology sector, focusing on developing therapies for serious diseases. With a market cap of $6 billion, the company is important for investors interested in innovative healthcare solutions and advancements in biotechnology.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and financial health, and investors will be looking for any signs of improvement.

$-0.78

Revenue

While no revenue is expected this quarter, any updates on future revenue streams or product launches could be significant.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-11.44%

Avg Stock Reaction

+0.88%

Last Quarter Recap

In Q4-2025, Scholar Rock reported an EPS of $-0.88, slightly missing expectations. The stock saw a modest increase of 1.91% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect a continued trend of losses, with an EPS estimate of $-0.78. Investors are particularly focused on any signs of operational progress or product development.

Bull Case

If the company can demonstrate significant advancements in its drug pipeline or unexpected revenue streams, it could lead to a positive reassessment of its future.

Bear Case

On the other hand, if losses widen or there are delays in product development, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

$-0.78

Earnings per share is a key indicator of profitability and financial health, and investors will be looking for any signs of improvement.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue streams or product launches could be significant.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS come in better than the consensus estimate of $-0.78?

A smaller loss than expected could signal operational improvements and boost investor confidence.

What updates can management provide on product development and future revenue streams?

Any positive news on upcoming therapies or partnerships could significantly impact the stock's outlook.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for operational improvements and pipeline advancements that could lead to better-than-expected results this quarter.

Supporting Evidence

The options market indicates a significant move, suggesting that investors anticipate volatility.

Recent insider selling could indicate a lack of confidence in short-term performance, which contrasts with potential long-term growth.

The historical trend of stock reactions suggests that even small improvements can lead to positive stock movements.

Key Risk

If the company announces any unexpected progress in its drug pipeline, it could challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it may indicate the company's ability to recover from previous losses and gain traction in the market.

Bull Confirmed If

A narrower EPS loss than $-0.78, coupled with positive commentary on product development, would confirm the bull case.

Bear Confirmed If

A wider EPS loss than $-0.78 with no updates on product progress would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.86%

Historical Avg

±5.7%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, indicating uncertainty among investors.

Options are pricing ±8.7% while SRRK has averaged ±5.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

50.7%

Calls (57K)P/C Ratio: 3.17Puts (800)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$3.1M

63,491 sh

4 insiders

Net

$3.1M

Net selling

Most Active Insiders· 4 open-market trades

Chief Executive OfficerHallal David
$1.5M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Scholar Rock beats EPS expectations, history suggests the stock could rise by around 1.56% on the following day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to a muted response as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of about 1.56%, which could raise concerns about its future viability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of drug candidates in the pipeline.
2Management's commentary on operational efficiency and cost management.
3Insights into potential partnerships or collaborations.
4Any changes in regulatory status or approvals.
5Guidance on future revenue expectations or product launches.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

AXSOME THERAPEUTICS

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and financial health, and investors will be looking for any signs of improvement.

$-0.78

Revenue

While no revenue is expected this quarter, any updates on future revenue streams or product launches could be significant.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-11.44%

Avg Stock Reaction

+0.88%

Last Quarter Recap

In Q4-2025, Scholar Rock reported an EPS of $-0.88, slightly missing expectations. The stock saw a modest increase of 1.91% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect a continued trend of losses, with an EPS estimate of $-0.78. Investors are particularly focused on any signs of operational progress or product development.

Bull Case

If the company can demonstrate significant advancements in its drug pipeline or unexpected revenue streams, it could lead to a positive reassessment of its future.

Bear Case

On the other hand, if losses widen or there are delays in product development, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

$-0.78

Earnings per share is a key indicator of profitability and financial health, and investors will be looking for any signs of improvement.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue streams or product launches could be significant.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS come in better than the consensus estimate of $-0.78?

A smaller loss than expected could signal operational improvements and boost investor confidence.

What updates can management provide on product development and future revenue streams?

Any positive news on upcoming therapies or partnerships could significantly impact the stock's outlook.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for operational improvements and pipeline advancements that could lead to better-than-expected results this quarter.

Supporting Evidence

The options market indicates a significant move, suggesting that investors anticipate volatility.

Recent insider selling could indicate a lack of confidence in short-term performance, which contrasts with potential long-term growth.

The historical trend of stock reactions suggests that even small improvements can lead to positive stock movements.

Key Risk

If the company announces any unexpected progress in its drug pipeline, it could challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it may indicate the company's ability to recover from previous losses and gain traction in the market.

Bull Confirmed If

A narrower EPS loss than $-0.78, coupled with positive commentary on product development, would confirm the bull case.

Bear Confirmed If

A wider EPS loss than $-0.78 with no updates on product progress would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.86%

Historical Avg

±5.7%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, indicating uncertainty among investors.

Options are pricing ±8.7% while SRRK has averaged ±5.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

50.7%

Calls (57K)P/C Ratio: 3.17Puts (800)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$3.1M

63,491 sh

4 insiders

Net

$3.1M

Net selling

Most Active Insiders· 4 open-market trades

Chief Executive OfficerHallal David
$1.5M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Scholar Rock beats EPS expectations, history suggests the stock could rise by around 1.56% on the following day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to a muted response as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of about 1.56%, which could raise concerns about its future viability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of drug candidates in the pipeline.
2Management's commentary on operational efficiency and cost management.
3Insights into potential partnerships or collaborations.
4Any changes in regulatory status or approvals.
5Guidance on future revenue expectations or product launches.